Antios Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
6
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:4
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (66.7%)Phase 2
2 (33.3%)Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects
Phase 1
Terminated
- Conditions
- Chronic Hepatitis b
- Interventions
- Drug: ATI-2173 50 mg
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Antios Therapeutics, Inc
- Target Recruit Count
- 37
- Registration Number
- NCT05298332
- Locations
- 🇺🇸
Altasciences, Cypress, California, United States
A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection
Phase 2
Terminated
- Conditions
- Chronic Hepatitis b
- Interventions
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Antios Therapeutics, Inc
- Target Recruit Count
- 2
- Registration Number
- NCT05238844
- Locations
- 🇲🇩
Republican Clinical Hospital "Timofei Mosneaga" Arensia EM Unit, Chisinau, Republic Of Moldova, Moldova, Republic of
🇺🇦Medical Center of Limited Liability Company "Harmoniya krasy", Kyiv, Ukraine
A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects
Phase 1
Completed
- Conditions
- Drug Drug Interaction
- Interventions
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Antios Therapeutics, Inc
- Target Recruit Count
- 36
- Registration Number
- NCT05137600
- Locations
- 🇨🇦
Altasciences, Montréal, Quebec, Canada
A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects
Phase 1
Completed
- Conditions
- Drug Interaction
- Interventions
- Drug: ATI-2173 50 mg
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Antios Therapeutics, Inc
- Target Recruit Count
- 32
- Registration Number
- NCT05137548
- Locations
- 🇨🇦
Altasciences, Montréal, Quebec, Canada
A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
Phase 2
Terminated
- Conditions
- Hepatitis DHepatitis B, Chronic
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Antios Therapeutics, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT04847440
- Locations
- 🇲🇩
Republican Clinical Hospital "Timofei Mosneaga" Arensia EM Unit, Chisinau, Republic Of Moldova, Moldova, Republic of
🇺🇦Medical Center of Limited Liability Company "Harmoniya krasy", Kyiv, Ukraine
- Prev
- 1
- 2
- Next
News
No news found